Connect with us

Press Release

Educational Awakening Center Announces “Decision Literacy” Initiative to Redefine Self-Awareness in the Age of Information Overload

Published

on

San Francisco, CA, 22nd May 2026, ZEX PR WIRE — Ariya Malek, CEO of Educational Awakening Center (EAC Seminars), today announced a new strategic direction focused on what the organization defines as “decision literacy,” a structured approach to self-awareness designed for individuals navigating increasing cognitive overload in the digital age.

The initiative marks a shift in emphasis from traditional personal development content toward building what EAC describes as cognitive infrastructure. Rather than offering motivation-based or purely inspirational material, the organization is developing frameworks that help individuals understand how decisions are formed, how attention is allocated, and how behavioral patterns are reinforced over time.

According to EAC, modern challenges are no longer limited to a lack of information but instead stem from excessive information without structure. The organization’s new focus aims to address this gap by teaching individuals how to interpret their own thinking processes with greater clarity and consistency. “This is not about adding more information,” said Malek. “It is about helping people understand how their thinking is structured so they can make decisions with intention rather than reaction.”

Under this initiative, Educational Awakening Center will expand its seminar frameworks to include structured learning models that break down decision-making into observable components. These models examine how environment, attention, belief systems, and repetition interact to produce behavioral outcomes. The goal is to move beyond awareness as a concept and position it as a measurable, trainable skill.

The organization’s approach reframes self-awareness as a form of literacy, similar to reading or writing. In this model, individuals are not simply encouraged to reflect; they are taught to systematically interpret their internal decision-making patterns. This includes identifying cognitive triggers, recognizing habitual response loops, and understanding how external inputs influence long-term behavior.

EAC Seminars will also expand its digital content distribution strategy across platforms, including Substack and X. These channels will be used to distribute simplified breakdowns of decision literacy concepts, allowing audiences to engage with structured insights in accessible formats.

In addition, Educational Awakening Center will continue to leverage its presence on Facebook and Instagram to share condensed learning modules and applied frameworks designed for everyday integration. These platforms will serve as entry points for individuals seeking practical tools to improve decision-making clarity without requiring formal seminar participation.

Malek’s ongoing contributions to the Forbes Councils will also support this initiative, with upcoming publications focusing on behavioral structure, attention economics, and the evolving role of self-awareness in modern leadership and personal development.

EAC describes the broader vision behind this shift as moving from content consumption to cognitive structure building. In this context, traditional personal development content is viewed as insufficient for addressing the complexity of modern decision environments. Instead, the organization is positioning structured awareness as a foundational skill for navigating both personal and professional challenges. “The problem today is not a lack of advice,” Malek explained. “The problem is that most people have never been taught how to interpret their own decision-making systems. Once that changes, everything else becomes clearer.”

The Decision Literacy Initiative will introduce a series of updated seminar modules that guide participants through practical mapping of their thought processes. These modules are designed to help individuals identify recurring patterns in judgment, emotional response, and behavioral repetition. The intent is to create a repeatable framework that individuals can apply across different areas of life, including career, relationships, and long-term planning.

Educational Awakening Center’s methodology emphasizes structured reflection rather than passive insight. Participants are encouraged to observe how decisions form in real time and to recognize the influence of internal and external variables. This process is intended to build long-term cognitive discipline rather than short-term motivation.

As part of the initiative, EAC is also developing a more defined content architecture system to ensure consistency across all educational materials. This includes aligning seminar content, digital publications, and social media insights under a unified framework of decision literacy principles.

The organization views this as a response to what it describes as “attention fragmentation,” where individuals struggle to maintain clarity due to constant exposure to competing inputs. By introducing structured interpretive tools, EAC aims to help individuals regain control over how they process information and make decisions.

Educational Awakening Center will begin rolling out updated seminar content and digital learning materials in phases over the coming months. The organization states that this initiative represents a long-term commitment to redefining self-awareness as a practical skill set rather than an abstract concept.

Through this expansion, EAC Seminars continues to position itself as a platform focused on structured learning systems that support deeper clarity, improved decision-making, and intentional personal development in an increasingly complex world.

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

STARTRADER Breaks Ground on Davao Basketball Court Revamp in the Philippines, Benefiting Around 20,000 People

Published

on

Davao City, Philippines, July 10th, 2026, FinanceWire

The project marks STARCARES’ latest CSR investment in accessible sports infrastructure for schools and communities.

STARTRADER has officially launched the redevelopment of the basketball court at Communal Elementary School in Buhangin, Davao City, with a groundbreaking ceremony held on site. Upon completion, the upgraded facility will benefit approximately 20,000 students, school staff, parents, and residents. It will serve approximately 2,000 learners, 72 school staff, 1,600 parents, and approximately 16,000 residents of Barangay Communal

The project responds to the need for a functional, well-maintained recreational space serving both Communal Elementary School and the wider Barangay Communal community. For students, it supports physical education, school assemblies, and organized sports. For residents, it provides a reliable venue for recreation and community activities. In a country where basketball brings people together, the upgraded court is designed to serve both groups equally.

The initiative builds on STARCARES’ growing global commitment to youth development through accessible sports infrastructure. Following successful basketball court revitalization projects in Vietnam and Thailand, the Philippines marks the next step in creating spaces where youth can learn, play, and grow.

“Breaking ground on this project is just the beginning. STARCARES exists to create lasting impact, and this court will provide thousands of students and residents in Buhangin with a safe, dependable place to learn, play, and come together for years to come.” Peter Karsten, CEO of STARTRADER.

“We are excited to see this project take shape. It will give our learners a safe space to grow, be active, and build confidence while bringing our community together during weekends. We are deeply grateful to STARTRADER and STARCARES.” Nelson Sepe Lubguban Jr., Principal of Communal Elementary School.

Looking ahead, STARCARES will expand its global basketball court initiative, with Lagos, Nigeria planned as the next redevelopment project, furthering its mission to create safe, inclusive sports spaces that empower youth and strengthen communities worldwide.

About STARTRADER

STARTRADER is a global multi-asset broker empowering retail and institutional partners to access global markets through a range of platforms, including MetaTrader, STAR-APP, and STAR-COPY.

Regulated in five jurisdictions (CMA, ASIC, FSCA, FSA, and FSC), STARTRADER combines strong governance with a client-first approach, serving both retail clients and partners with a commitment to transparency, reliability, and long-term growth.

Contact

Janna Magabilen
Janna.magabilen@startrader.com

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Philip Ashton-Rickardt Says the Next Generation of Medical Breakthroughs Will Need More Scientist-Entrepreneurs

Published

on

  • Boston biotech leader Philip Ashton-Rickardt believes more researchers should take their discoveries beyond the laboratory and into the real world, where they can improve lives.

Massachusetts, USA, Jul 10, 2026, ZEX PR WIRE — Philip Ashton-Rickardt, Managing Director and Chief Scientific Officer of BE Therapeutics, is encouraging more scientists to consider entrepreneurship as part of their career journey, arguing that the next generation of medical breakthroughs will depend not only on scientific discovery but also on the people willing to transform those discoveries into real-world treatments.

After more than two decades in academia, including professorships at the University of Chicago and Imperial College London, Ashton-Rickardt decided to leave university research and enter biotechnology. Since then, he has founded and helped lead multiple companies in developing advanced cell therapies for neurological diseases, driven by a desire to move promising science closer to patients.

“The goal was never simply to publish another paper,” said Ashton-Rickardt. “I wanted to help build therapies that could eventually improve people’s lives. That meant stepping outside my comfort zone and learning an entirely new way of thinking.”

His message comes as more researchers look beyond traditional academic careers. According to the Association of University Technology Managers (AUTM), U.S. research institutions launched more than 1,100 startups based on university discoveries in 2023, reflecting growing momentum to translate scientific research into real-world products and therapies. Ashton-Rickardt believes that trend is especially important in biotechnology, where scientific discoveries often need entrepreneurial leadership to reach patients.

“An idea only becomes valuable when people work together to test it,” he said. “Science doesn’t move forward because one person has all the answers. It moves forward because people with different expertise challenge each other and build something better together.”

Ashton-Rickardt believes scientists often possess many of the qualities needed to become successful entrepreneurs, even if they don’t always recognise it. Years spent solving complex problems build resilience, curiosity, adaptability, and the ability to learn from failure. Those same qualities are essential for creating companies capable of translating discoveries into therapies.

“I’ve never been afraid to leave my comfort zone,” he said. “Every major step in my career felt uncertain at the time, but those decisions opened opportunities I never could have planned.”

Growing up in a working-class family in the United Kingdom also shaped his outlook. He says learning to create his own opportunities gave him the confidence to move between academia, startups, and leadership roles across the biotechnology industry.

“We sometimes think we have to choose between being a scientist and being an entrepreneur,” Ashton-Rickardt said. “I don’t see those as competing paths. I see entrepreneurship as another way of applying science to solve important problems.”

He also believes curiosity remains one of the most valuable qualities any scientist can develop.

“The moment you think you’ve learned enough is usually the moment you stop growing,” he said. “The best scientists and the best entrepreneurs never stop asking questions.”

Looking Ahead

Ashton-Rickardt hopes more scientists will see entrepreneurship as a natural extension of research rather than a departure from it. While publishing discoveries remains an important part of scientific progress, he believes researchers should also think about how those discoveries can become products, therapies, and technologies that improve people’s lives.

“If you have an idea that could genuinely make a difference, don’t assume someone else will take it forward,” Ashton-Rickardt said. “Stay curious, keep asking questions, and don’t be afraid to build something new.”

About Philip Ashton-Rickardt

Philip Ashton-Rickardt is the Managing Director and Chief Scientific Officer of BE Therapeutics. A molecular immunologist by training, he earned his PhD from the University of Edinburgh before completing postdoctoral research at the Massachusetts Institute of Technology. After distinguished academic careers at the University of Chicago and Imperial College London, he transitioned into biotechnology entrepreneurship, founding and leading multiple companies focused on developing innovative cell therapies for neurological and immune-related diseases. He has also held leadership roles at Sigilon Therapeutics, Flagship Pioneering, and Halyard Therapeutics. Today, his work focuses on advancing engineered cell therapies that have the potential to improve the treatment of neurological disorders while helping bridge the gap between scientific discovery and real-world patient care.

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Vantage Vascular Selected for National RESORB Knee test Brooklyn NY and Fair Lawn NJ

Published

on

Vantage Vascular is one of just over 10 U.S. practices chosen to participate in the landmark RESORB clinical test for knee osteoarthritis pain.

Brooklyn, NY, United States, 10th Jul 2026 – Vantage Vascular, an outpatient vascular and interventional radiology practice serving patients across New York and New Jersey, has been selected as one of just over 10 leading U.S. clinical sites chosen to participate in the RESORB clinical test, a landmark national study evaluating a breakthrough, non-surgical treatment for knee osteoarthritis pain. 

Being named a RESORB test site is not automatic. NEXTBIOMEDICAL, the study sponsor, specifically sought out practices with the clinical expertise, imaging capabilities, and patient-first infrastructure to effectively conduct a pivotal FDA test. 

RESORB (Randomized Controlled Study Evaluating Genicular Artery Embolization Against Intra-Articular Corticosteroid Knee Injection for Osteoarthritic Knee Pain) is a pivotal, FDA-approved clinical test comparing genicular artery embolization (GAE) using an investigational device called Nexsphere F to a standard corticosteroid knee injection. The test is enrolling approximately 126 patients across more than 10 U.S. sites and is registered on ClinicalTrials.gov as NCT06872567.

Genicular artery embolization is a minimally invasive, outpatient procedure in which board-certified interventional radiologists use image guidance to deliver tiny particles into blood vessels feeding the inflamed tissues of the knee.

Nexsphere F is a novel, fast-resorbable microsphere technology. Unlike permanent embolic agents, Nexsphere F microspheres dissolve naturally within 2 to 6 hours after the procedure.

Term blockage of blood flow. The device has already received FDA Breakthrough Device Designation, CMS IDE Category B approval (meaning Medicare covers the procedure during the test), and CE-MDD certification in Europe, where it has been used in thousands of procedures with a strong safety record.

Why Being a Selected test Site Matters for Patients

Clinical test site selection for an FDA pivotal study is highly competitive. Sponsors identify practices based on physician expertise, procedural volume, imaging infrastructure, and the ability to safely manage research protocols. 

For patients, what this means in practice is significant: Vantage Vascular is offering access to a treatment not yet available anywhere outside of these select test sites in the United States. If you have knee osteoarthritis pain that has persisted despite medications and conservative care for at least two months, and you are not currently planning knee surgery or replacement, you may be eligible to receive this FDA-monitored, cutting-edge procedure at no cost through the test.

The test’s national Principal Investigator and Chief Medical Officer for NEXTBIOMEDICAL is Dr. Ziv J. Haskal, MD, Professor of Interventional Radiology at the University of Virginia. The clinical evidence behind Nexsphere F continues to grow: a published study in the Journal of Vascular and Interventional Radiology evaluating 155 patients treated with resorbable microspheres found a 67% average reduction in pain at 6 months, with no device-related serious adverse events.

Who May Be Eligible

The RESORB test is enrolling adults who:

• Have knee osteoarthritis pain that has not responded adequately to conservative treatments for at least 2 months

• Are not currently planning knee surgery or knee replacement

• Meet the study’s eligibility criteria as reviewed by Vantage Vascular’s clinical team

If enrolled, participants are randomly assigned to receive either GAE with Nexsphere F or a corticosteroid knee injection. Those initially assigned to the corticosteroid injection have the option to receive GAE after 180 days. The test runs approximately 12 to 18 months, and participation is always voluntary.

The test is FDA-IDE and IRB-approved (IRB approval at the protocol level: October 31, 2025). During the test, the procedure is covered under CMS IDE Category B, meaning Medicare-eligible patients may have coverage for test participation.

Schedule a Consultation at Vantage Vascular

If you or someone you know has been living with chronic knee pain, now is the time to explore whether you qualify. Vantage Vascular’s team will evaluate your history, imaging, and treatment background to determine eligibility and walk you through every step of the process with the same compassionate, patient-first care the practice is known for.

Enrollment is currently open at Vantage Vascular’s Brooklyn and New Jersey locations. Call or visit the practice online to schedule a consultation.

Brooklyn Flatlands Clinic: 2035 Ralph Ave, Suite B5, Brooklyn, NY 11234

Brooklyn Midwood Clinic: 603 Rugby Road, Suite 3, Brooklyn, NY 11230

New Jersey Fair Lawn Clinic: 15-01 Broadway, Suites 1–3, Fair Lawn, NJ 07410

NY: (718) 247-8794 | NJ: (201) 812-2929 | Monday–Friday: 8AM–6PM | vantagevascular.com

About Vantage Vascular

Vantage Vascular is an outpatient vascular and interventional radiology practice with locations in Brooklyn, New York and Fair Lawn, New Jersey. Led by Dr. Vishal K. Sinha, MD (Founder & President) and Dr. Christopher M. Harnain, MD, MBA, RPVI (Chief of Interventional Radiology & Founding Member), the practice’s Ivy League-educated, board-certified interventional radiologists deliver world-class, minimally invasive treatments for joint pain, vascular conditions, women’s health, and more — all in a comfortable outpatient setting, with no hospital stays or prolonged recovery. Vantage Vascular is dedicated to advancing patient care through innovation, clinical excellence, and a deep commitment to the communities of New York and New Jersey.

About the RESORB test

RESORB is a randomized, open-label, FDA-IDE and IRB-approved pivotal clinical test evaluating genicular artery embolization with Nexsphere F  against intra-articular corticosteroid knee injection for osteoarthritic knee pain. The study is registered on ClinicalTrials.gov as NCT06872567, with an estimated enrollment of 126 participants at more than 10 leading U.S. clinical sites. Nexsphere F has received FDA Breakthrough Device Designation, CMS IDE Category B approval, and CE-MDD certification in Europe.

Important Research Notice

Nexsphere F is an investigational device not yet approved or cleared by the FDA for commercial use in the United States. It is available only through the RESORB clinical test at authorized test sites. Participation is subject to eligibility criteria, informed consent, site availability, and investigator review. Individual results may vary. Medicare coverage under CMS IDE Category B applies to eligible participants during the test period; patients should confirm coverage with Vantage Vascular and their insurer.

Media Contact

Organization: Vantage Vascular

Contact Person: Vishal K. Sinha

Website: https://vantagevascular.com/

Email: Send Email

Contact Number: +17182478794

Address:2035 Ralph Ave Ste B

City: Brooklyn

State: NY

Country:United States

Release id:46614

The post Vantage Vascular Selected for National RESORB Knee test Brooklyn NY and Fair Lawn NJ appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST